articlePEDIATRICSJan 31, 2012Closed access

Neonatal Drug Withdrawal

United States Food and Drug Administration · American Congress of Obstetricians and Gynecologists · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.

Citation impact

874
total citations
FWCI
73.22
Percentile
100%
References
186
Citations per year

Authors

17

Topics & keywords

Keywords
  • Medicine
  • Drug withdrawal
  • Drug
  • Pregnancy
  • Sedation
  • Intensive care medicine
  • Anesthesia
  • Pediatrics
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.